MTL Cannabis Corp. Adjusts Meeting Schedule Amid Canadian Postal Strike

PICKERING, ON, Nov. 22, 2024 /CNW/ – MTL Cannabis Corp. MTLC (“MTL” or the “Company“) has announced the rescheduling of its Annual General and Special Meeting (the “Meeting“) originally set for Thursday, December 12, 2024, due to a strike affecting Canadian postal services. The decision to adjourn the meeting was made to fulfill notification and delivery laws required by corporate and securities legislation. The record date will remain unchanged, but the proxy cut-off date has been extended to 9:00 am (Vancouver Time) on December 24, 2024. The Meeting will now take place on December 30, 2024, at 9:00 am (Vancouver Time). Meeting materials can be accessed on the Company’s profile at www.sedarplus.ca and on their website at www.mtlcorp.ca/investors. If the Postal Strike is resolved before the Meeting date, materials will be mailed out as usual.

Registered shareholders will receive emails from the Company’s transfer agent, Odyssey Trust Company, containing their proxy and voting control numbers along with voting instructions. Anyone not receiving this email should reach out to Odyssey Trust Company at 1-888-290-1175 or via email at shareholder@odysseytrust.com to obtain their proxy information.

Beneficial holders are advised to contact their brokers for a voting information form, voting control number, and voting instructions.

Additionally, the Company’s financial statements and management discussions can be found on its profile at www.sedarplus.ca, and hard copies will be sent once the postal situation normalizes.

About MTL Cannabis Corp.

MTL is the parent of MTL Cannabis, a licensed producer operating a 57,000 sq ft indoor grow facility in Pointe Claire, Québec, Abba Medix Corp., a licensed producer in Pickering, Ontario, known for its medical cannabis marketplace, IsoCanMed Inc., a licensed producer in Louiseville, Québec, with a 64,000 sq. ft. production facility, and Canada House Clinics Inc., which operates multiple clinics across Canada to deliver specialized cannabinoid therapies for patients facing various medical challenges.

Focusing on flower-first products, MTL Cannabis employs unique hydroponic growing methods paired with artisanal techniques to foster high-quality cannabis outputs. It markets its products under the “MTL Cannabis,” “Low Key by MTL,” and “R’belle” brands, utilizing nine distribution partnerships with provincial cannabis distributors. MTL Cannabis is also exploring several export channels for bulk and unbranded GACP quality cannabis.

The Company aims for Abba Medix Corp. to lead the medical cannabis distribution landscape in Canada, while Canada House Clinics aspires to become the foremost provider of medical cannabis clinic services within the country.

For more details, visit www.mtlcorp.ca or check the Company’s public filings at www.sedarplus.ca.

Cautionary Statement Regarding Forward-Looking Information.

This press release includes forward-looking statements that pertain to MTL’s clinics, production capabilities, technological advancements, and future plans. Such statements can typically be identified by terms like “may,” “will,” “could,” “likely,” “expect,” and “believe.” While the Company deems these expectations to be reasonable, they entail risks and uncertainties. Real outcomes may differ significantly from those discussed. Factors affecting these outcomes include regulatory conditions under the Cannabis Act (Canada), financial resources, market competition, adaptability of products and services, and executive retention. Comprehensive risk factors can be found in the Company’s Listing Statement dated August 14, 2023 and related documents filed with Canadian securities authorities. The Company does not commit to updating any forward-looking statements unless required by law.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE MTL Cannabis Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2024/22/c3120.html